Inclusion Criteria:

        Has histologically or cytologically confirmed, locally advanced, metastatic cancer meeting
        the following criteria:

        Phase 1 Expansion

          1. Patient has failed all standard therapies or standard therapy does not exist or is not
             tolerated.

          2. Patient has specific FGF/FGFR aberrations

               -  Intrahepatic or extrahepatic cholangiocarcinoma with FGFR2 gene fusions or other
                  FGFR2 abnormalities, i.e., gene mutations (see Appendix A), rearrangements or
                  amplifications

               -  Glioblastoma or grade III glioma (i.e., anaplastic astrocytoma or anaplastic
                  oligodendroglioma) with FGFR gene fusions or activating mutations.

               -  Advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations

               -  All other tumor types harboring FGF9, FGF19 or FGFR2 amplifications (≥ 10
                  copies), FGFR gene fusions, or FGFR activating mutations

        Phase 2

          1. Patient has histologically or cytologically confirmed, locally advanced, metastatic,
             unresectable iCCA harboring FGFR2 gene fusions based on results from a NGS assay by
             the Sponsor's designated central laboratory

          2. Patient has been treated with and failed at least one prior systemic gemcitabine and
             platinum-based chemotherapy for the advanced disease

          3. Must have documentation of radiographic progression of disease on prior systemic
             therapy

          4. Patient has measurable disease as defined by Response Evaluation Criteria in Solid
             Tumors (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or RANO
             criteria (2010) for brain tumors.

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          6. Adequate organ function

        Exclusion Criteria:

        A patient will be excluded from this study if any of the following criteria are met:

          1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus
             homeostasis.

          2. History and/or current evidence of clinically significant ectopic
             mineralization/calcification.

          3. History and/or current evidence of clinically significant retinal disorder confirmed
             by retinal examination.

          4. A serious illness or medical condition(s)